Gland Pharma Q2 FY27 consolidated PAT up 58% YoY to Rs 290.8 crore
Gland Pharma’s Q2 FY27 consolidated revenue from operations was Rs 1,833.60 cr, with PAT at Rs 290.80 cr versus Rs 183.70 cr in Q2 FY26.
Key takeaways
- Rs 1,833.60 cr revenue from operations in Q2 FY27 vs Rs 1,486.90 cr in Q2 FY26
- Rs 1,902.60 cr total income in Q2 FY27 vs Rs 1,571.00 cr a year earlier
- Rs 1,471.70 cr total expenses in Q2 FY27 vs Rs 1,287.10 cr in Q2 FY26
- Rs 290.80 cr PAT in Q2 FY27 vs Rs 183.70 cr in Q2 FY26
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 1,833.60 cr | Rs 1,486.90 cr | +23.3% |
| PAT | Rs 290.80 cr | Rs 183.70 cr | +58.3% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 15.86% of revenue, up 350 bps from 12.35%.
- Revenue rose 23.3% while total expenses rose 14.3%.
• Revenue from operations (Q2 FY27, consolidated): Rs 1,833.60 cr (Q2 FY26: Rs 1,486.90 cr)
• Total income (Q2 FY27, consolidated): Rs 1,902.60 cr (Q2 FY26: Rs 1,571.00 cr)
• Total expenses (Q2 FY27, consolidated): Rs 1,471.70 cr (Q2 FY26: Rs 1,287.10 cr)
• Profit before tax – PBT (Q2 FY27, consolidated): Rs 430.90 cr (Q2 FY26: Rs 283.90 cr)
• Profit after tax – PAT (Q2 FY27, consolidated): Rs 290.80 cr (Q2 FY26: Rs 183.70 cr)
The numbers above are taken from the consolidated statement of financial results for the quarter ended 30 September 2026 (Q2 FY27), with comparison to the corresponding quarter ended 30 September 2025 (Q2 FY26), as presented in the investor presentation’s consolidated P&L table on the financial highlights slide.
According to the consolidated P&L in the statement of financial results, revenue from operations for Q2 FY27 stood at Rs 1,833.60 cr, up from Rs 1,486.90 cr in Q2 FY26. Including other income, total income reached Rs 1,902.60 cr in Q2 FY27 versus Rs 1,571.00 cr a year earlier. On the cost side, total expenses were Rs 1,471.70 cr in Q2 FY27 compared with Rs 1,287.10 cr in Q2 FY26, as per the same consolidated results table.
With income rising faster than expenses, profit before tax (PBT) increased to Rs 430.90 cr in Q2 FY27 from Rs 283.90 cr in Q2 FY26, based on the consolidated statement of financial results. After tax, profit after tax (PAT) for the quarter came in at Rs 290.80 cr, compared with Rs 183.70 cr in the corresponding quarter of the previous year.
The investor presentation’s consolidated P&L slide also shows supporting profitability indicators built off these lines: Gross Profit of Rs 1,163.80 cr in Q2 FY27 versus Rs 933.10 cr in Q2 FY26, and EBITDA of Rs 480.40 cr versus Rs 313.90 cr. The company additionally discloses Adj. EBITDA of Rs 503.00 cr in Q2 FY27 against Rs 335.50 cr in Q2 FY26 on the same slide, alongside the stated gross profit, EBITDA and PAT margins.
Management commentary in the presentation attributes revenue trends to both the CDMO and Critical Injectables businesses, with the business-wise revenue table indicating Q2 FY27 CDMO revenue of Rs 822.70 cr and Critical Injectables revenue of Rs 1,010.90 cr, summing to the consolidated revenue from operations figure of Rs 1,833.60 cr reported in the consolidated statement of financial results.
Track Gland Pharma Ltd
Cruxal reads every Gland Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
